All In Biotech

Drug Trial Radar · NCT00566891

Safety of High-dose Tirofiban During Coronary Angioplasty

Safety of High-dose Tirofiban in Patient Undergoing Coronary Angioplasty.

Last checked: Nov 20, 2026Latest source record: Feb 2, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2,000

Actual

Start

Dec 2007

Primary completion

Jul 2008

Study completion Feb 2009

Sponsor

Lead sponsor
S. Anna HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 4, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This single-centre study is intended to retrospectively check the safety of high-dose bolus of tirofiban in patients who underwent percutaneous angioplasty.

Conditions

  • Coronary Artery Disease

Interventions

  • tirofibanDrug

    tirofiban high dose bolus 25µ/Kg

  • ClopidogrelDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measure: all cause mortalityTime frame: one year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • S Anna Hospital

    Catanzaro, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.